615 related articles for article (PubMed ID: 11440745)
1. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
[TBL] [Abstract][Full Text] [Related]
2. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
[TBL] [Abstract][Full Text] [Related]
3. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.
Marek K; Innis R; van Dyck C; Fussell B; Early M; Eberly S; Oakes D; Seibyl J
Neurology; 2001 Dec; 57(11):2089-94. PubMed ID: 11739831
[TBL] [Abstract][Full Text] [Related]
4. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
[TBL] [Abstract][Full Text] [Related]
5. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
6. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
[TBL] [Abstract][Full Text] [Related]
7. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity.
Kim SE; Lee WY; Choe YS; Kim JH
Neurol Res; 1999 Apr; 21(3):255-61. PubMed ID: 10319333
[TBL] [Abstract][Full Text] [Related]
8. [Dopamine transporter SPECT in patients with Parkinson's disease].
Hamano T; Tsuchida T; Hirayama M; Fujiyama J; Mutoh T; Yonekura Y; Kuriyama M
Kaku Igaku; 2000 Mar; 37(2):125-9. PubMed ID: 10783572
[TBL] [Abstract][Full Text] [Related]
9. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
Ahlskog JE; Uitti RJ; O'Connor MK; Maraganore DM; Matsumoto JY; Stark KF; Turk MF; Burnett OL
Mov Disord; 1999 Nov; 14(6):940-6. PubMed ID: 10584667
[TBL] [Abstract][Full Text] [Related]
10. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
11. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
[TBL] [Abstract][Full Text] [Related]
12. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
[TBL] [Abstract][Full Text] [Related]
13. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.
Haapaniemi TH; Ahonen A; Torniainen P; Sotaniemi KA; Myllylä VV
Mov Disord; 2001 Jan; 16(1):124-30. PubMed ID: 11215571
[TBL] [Abstract][Full Text] [Related]
14. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
[TBL] [Abstract][Full Text] [Related]
15. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
Kim SE; Choi JY; Choe YS; Choi Y; Lee WY
J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
[TBL] [Abstract][Full Text] [Related]
16. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.
Asenbaum S; Brücke T; Pirker W; Podreka I; Angelberger P; Wenger S; Wöber C; Müller C; Deecke L
J Nucl Med; 1997 Jan; 38(1):1-6. PubMed ID: 8998140
[TBL] [Abstract][Full Text] [Related]
17. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
[TBL] [Abstract][Full Text] [Related]
18. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.
Walker Z; Costa DC; Walker RW; Lee L; Livingston G; Jaros E; Perry R; McKeith I; Katona CL
Neurology; 2004 May; 62(9):1568-72. PubMed ID: 15136683
[TBL] [Abstract][Full Text] [Related]
19. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
20. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.
Ichise M; Kim YJ; Erami SS; Ballinger JR; Vines D; Tanaka F; Lang AE
J Nucl Med; 1999 Apr; 40(4):530-8. PubMed ID: 10210210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
